共 50 条
Can we defeat meningococcal disease in low and middle income countries?
被引:5
|作者:
Greenwood, Brian
[1
]
Chiarot, Emiliano
[2
]
MacLennan, Calman A.
[3
]
O'Ryan, Miguel
[4
]
机构:
[1] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1E 7HT, England
[2] Novartis Vaccines & Diagnost, Siena, Italy
[3] Novartis Vaccines Inst Global Hlth, Siena, Italy
[4] Univ Chile, Santiago, Chile
来源:
基金:
英国医学研究理事会;
关键词:
Meningococcus;
Vaccines;
Control;
ACUTE BACTERIAL-MENINGITIS;
NEISSERIA-MENINGITIDIS;
EPIDEMIOLOGY;
SURVEILLANCE;
CHILDREN;
VACCINES;
BELT;
ASIA;
D O I:
10.1016/j.vaccine.2011.12.063
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
The development of multivalent conjugate and protein-based meningococcal vaccines may make global control of meningococcal disease possible. However, achieving control of meningococcal disease in low and middle income countries will be challenging. In low income countries whose vaccination programmes receive financial support from the Global Alliance for Vaccination and Immunisation, the main challenge is lack of sufficient epidemiological information to allow rational decisions on vaccine introduction to be made and, in these countries, enhanced surveillance is needed. In middle income countries, financial challenges predominate. These could be met by demonstration of the cost effectiveness of new meningococcal vaccines and through the introduction of a tiered-pricing system. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:B63 / B66
页数:4
相关论文